Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.

Summary

This phase I, first-in-human dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK) profile, and preliminary antitumor activity of PLB1003.

Timeline

Start

2016-11-08

Primary completion

2020-12-30

Completion

2021-12-30

Drugs

Indications